Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Front Matter....Pages i-ix
Front Matter....Pages 1-1
Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins....Pages 3-22
Antibody–Drug Conjugate Development....Pages 23-38
Front Matter....Pages 39-39
Assay Methodologies and Challenges....Pages 41-56
Clinical Pharmacology Strategies in the Development of Antibody–Drug Conjugates....Pages 57-75
Predictive Biomarkers for Antibody–Drug Conjugates....Pages 77-90
Front Matter....Pages 91-91
Factors Involved in the Design of Cytotoxic Payloads for Antibody–Drug Conjugates....Pages 93-115
Linker Technology and Impact of Linker Design on ADC Properties....Pages 117-135
Front Matter....Pages 137-137
Antibody–Drug Conjugates for the Treatment of B-Cell Malignancies....Pages 139-147
Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies....Pages 149-160
Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies....Pages 161-175
Front Matter....Pages 177-177
Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer with a Focus on Breast Cancer....Pages 179-210
CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)....Pages 211-220
Case Study: An Antibody–Drug Conjugate Targeting MUC16 for Ovarian Cancer....Pages 221-239
EphA2 Immunoconjugate....Pages 241-253
Anti-PSMA Antibody-Drug Conjugates and Immunotoxins....Pages 255-272
Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine....Pages 273-293
Front Matter....Pages 295-295
Studies on the Metabolism of Antibody–Drug Conjugates....Pages 297-316
Front Matter....Pages 317-317
Design, Development, and Characterization of Recombinant Immunotoxins Targeting HER2/neu....Pages 319-348
The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors....Pages 349-367
Back Matter....Pages 369-375